Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of “Buy” from Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR) has received a consensus recommendation of “Buy” from the thirteen research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $106.20.

A number of brokerages recently issued reports on MNPR. Chardan Capital upped their price target on Monopar Therapeutics from $85.00 to $100.00 and gave the company a “buy” rating in a report on Sunday, November 9th. Oppenheimer set a $115.00 price objective on shares of Monopar Therapeutics and gave the stock an “outperform” rating in a research report on Thursday, October 2nd. Piper Sandler set a $95.00 target price on shares of Monopar Therapeutics and gave the company an “overweight” rating in a report on Thursday, September 25th. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, Leerink Partnrs raised shares of Monopar Therapeutics to a “strong-buy” rating in a research report on Monday, November 10th.

Monopar Therapeutics Price Performance

NASDAQ:MNPR opened at $74.61 on Monday. Monopar Therapeutics has a 12 month low of $21.00 and a 12 month high of $105.00. The firm has a market capitalization of $498.39 million, a PE ratio of -21.69 and a beta of 1.46. The business’s fifty day moving average price is $84.16 and its 200 day moving average price is $57.73.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.02). As a group, equities analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Buying and Selling at Monopar Therapeutics

In related news, major shareholder Tactic Pharma Llc sold 550,229 shares of the company’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the sale, the insider directly owned 272,026 shares of the company’s stock, valued at $17,303,573.86. This represents a 66.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

Large investors have recently modified their holdings of the company. TCG Crossover Management LLC purchased a new position in shares of Monopar Therapeutics during the third quarter worth approximately $12,496,000. Alyeska Investment Group L.P. purchased a new stake in Monopar Therapeutics in the 3rd quarter valued at $998,000. Vivo Capital LLC acquired a new stake in Monopar Therapeutics during the 3rd quarter worth $7,391,000. Ally Bridge Group NY LLC grew its position in Monopar Therapeutics by 86.6% during the 3rd quarter. Ally Bridge Group NY LLC now owns 64,455 shares of the company’s stock worth $5,264,000 after purchasing an additional 29,918 shares during the last quarter. Finally, Deerfield Management Company L.P. purchased a new position in Monopar Therapeutics during the 3rd quarter worth $13,048,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.